Abstracts tagged "Biologics"

Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 2824 • 2018 ACR/ARHP Annual Meeting
On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
Hanna Gul¹, Frederique Ponchel² and Paul Emery³, ¹Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Tapering of disease-modifying therapy (DMARDs) is recommended by EULAR/ACR for rheumatoid arthritis (RA) patients who achieve sustained remission on stable therapy. However, there is…
Abstract Number: 698 • 2018 ACR/ARHP Annual Meeting
Discontinuation of Methotrexate or TNF Inhibitors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Michael D. George¹, Joshua Baker² and Alexis Ogdie³, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Methotrexate and TNF inhibitors (TNFi) are commonly used in the treatment of RA, PsA, and other SpA. While MTX is a mainstay of RA…
Abstract Number: 2143 • 2018 ACR/ARHP Annual Meeting
Lymphoproliferative Malignancy in Psoriatic Arthritis and the Role of Systemic Immunosuppressive Therapies
Linh Truong¹ and Maida Wong², ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Division of Rheumatology, University of California, Irvine, Orange, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that can have musculoskeletal (PsA-MsK) or concurrent MsK and skin (PsA-MsK/skin) manifestations, and the skin disease…
Abstract Number: 2576 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Christopher T. Ritchlin¹, Joseph F. Merola², Amanda M. Gellett³, Chen-Yen Lin³ and Talia Muram³, ¹University of Rochester Medical Center, Rochester, NY, ²Clinical Unit for Research Innovation & Trials, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Anti-drug antibody (ADA) development can potentially affect the efficacy of biologics; concomitant MTX decreases the development of ADA for some biologics.1 Ixekizumab (IXE), a…
Abstract Number: 2862 • 2018 ACR/ARHP Annual Meeting
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Rosemary Peterson¹, Rui Xiao², Timothy G. Brandon³, David M. Biko⁴, Michael Francavilla⁴, Nancy A. Chauvin⁵ and Pamela F. Weiss⁶, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Radiology, Penn State Hershey Medical Center, Hershey, PA, ⁶Pediatrics, Children's Hospital Philadelphia, Philadelphia, PA
Background/Purpose: We aimed to quantify the magnitude of biologic effect on sacroiliitis in juvenile SpA by comparing the change in the Spondyloarthritis Research Consortium of…
Abstract Number: 11L • 2017 ACR/ARHP Annual Meeting
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
Lene Dreyer¹, René Cordtz², Inger Marie J. Hansen³, Lars Erik Kristensen⁴, Merete Lund Hetland⁵ and Lene Mellemkjær⁶, ¹Center for Rheumatology and Spine Diseases, Gentofte University Hospital,Rigshospitalet, Hellerup, Denmark, ²Center for Rheumatology and Spine Diseases, Gentofte University Hospital, Rigshospitalet, Hellerup, Denmark, ³Department of Reumatology, OUH, Svendborg Hospital, Svendborg, Denmark, ⁴The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen F, Denmark, ⁵DANBIO, Glostrup Hospital.On behalf of all Depts of Rheumatology in Denmark.Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ⁶Danish Cancer Society Research Center, Copenhagen, Denmark, Copenhagen, Egypt

Background/Purpose: The safety of treatment with biological DMARDs (bDMARDs) has been carefully studied for the past 15 years, however, it is still largely unknown whether…
Abstract Number: 202 • 2017 ACR/ARHP Annual Meeting
Analysis of Provider-to-Provider Variability in the Use of Biologics: Data from the Rheumatology Informatics System for Effectiveness Registry
Douglas White¹, Michael Evans², Gabriela Schmajuk³, Rachel Myslinski⁴, Salahuddin Kazi⁵ and Jinoos Yazdany⁶, ¹Gundersen Health System, Onalaska, WI, ²University of California San Francisco, San Francisco, CA, ³San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁴Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA, ⁵University of Texas Southwestern, Dallas, TX, ⁶Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Variations in biologic prescribing habits by rheumatology providers may account in part for variability in direct cost of care for patients with rheumatoid arthritis…
Abstract Number: 621 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Improvement in Major and Moderate Response of Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Josef S. Smolen¹, Philip J Mease², Christopher T. Ritchlin³, Tore K Kvien⁴, Luminita Pricop⁵, Todd Fox⁶, Lawrence Rasouliyan⁷, Steffen Jugl⁶ and Corine Gaillez⁶, ¹Medical University of Vienna, Vienna, Austria, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷RTI Health Solutions, Barcelona, Spain
Background/Purpose: DAPSA score is a validated tool to measure disease activity states and response criteria, focusing on peripheral joint involvement in patients (pts) with PsA.1…
Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Muhammad Shipa¹, Maria Di Cicco², Emese Balogh², Aneela Mian³, Dev Mukerjee⁴ and Euthalia Roussou², ¹Rheumatology and General internal Medicine, North Middlesex University Hospital NHS trust, London, United Kingdom, ²Barking Havering and Redbridge University hospitals NHS Trust, London, United Kingdom, ³Rheumatology, King's College London, London, United Kingdom, ⁴Rheumatology, North Middlesex University Trust, London, United Kingdom
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…
Abstract Number: 1785 • 2017 ACR/ARHP Annual Meeting
Serious or Opportunistic Infections in Infants Born to Pregnant Women with Rheumatoid Arthritis and Treated with a Biologic Medication
Christina D Chambers¹, Diana L Johnson², Yunjun Luo³, Ronghui Xu⁴ and Kenneth L Jones³, ¹Pediatrics and Family Medicine and Public Health, University of California San Diego, La Jolla, CA, ²Department of Pediatrics, University of California, San Diego, La Jolla, CA, ³Pediatrics, University of California San Diego, La Jolla, CA, ⁴Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA
Background/Purpose: Use of biologic therapies for rheumatoid arthritis (RA) in pregnancy is common. There is theoretical concern that these medications could interfere with postnatal…
Abstract Number: 2520 • 2017 ACR/ARHP Annual Meeting
Incidence of Extra-Articular Manifestations in Psa and As Patients Treated with Golimumab in Canadian Real-World
Michelle Teo¹, Derek Haaland², John Kelsall³, Isabelle Fortin⁴, Pauline Boulos⁵, Raman Rai⁶, Sanjay Dixit⁷, B Haraoui⁸, Dalton Sholter⁹, Eliofotisti Psaradellis¹⁰, Emmanouil Rampakakis¹⁰, Brendan Osborne¹¹, Francois Nantel¹¹ and Allen J Lehman¹², ¹Balfour Medical Clinic, Penticton, BC, Canada, ²Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ³Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁴Centre de Rhumatologie De l’Est du Quebec, Rimouski, QC, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Private Practice, Hamilton, ON, Canada, ⁷Rheumatology, McMaster University Hamilton, Burlington, ON, Canada, ⁸Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose: Spondyloarthropathies (SpA) encompass a heterogeneous group of chronic inflammatory diseases affecting axial and peripheral joints. Besides articular symptoms, patients also experience extra-articular manifestations (EAMs)…
Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…
Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Laura C Coates¹, Peter Nash², Tore Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Steffen Jugl⁸, Kunal Gandhi⁷, Corine Gaillez⁸ and Josef S. Smolen⁹, ¹University of Oxford, Leeds, Great Britain, ²University of Queensland, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Swedish Medical Center and University of Washington, Seattle, WA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
Abstract Number: 1447 • 2017 ACR/ARHP Annual Meeting
Smoking Reduces Efficacy of Biologics Differently By Target Cytokines in Rheumatoid Arthritis
Kentaro Kuzuya¹, Yukihiko Saeki², Jun Hashimoto³, Shirou Oshima⁴, Masato Matsushita⁵, Souichirou Tuji⁴, Yoshinori Harada⁶, Maiko Yoshimura⁶, Satoru Teshigawara⁶ and Hidetoshi Matsuoka⁴, ¹Rheumatology and Allegology, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ²Dept of Clinical research, Osaka-Minami Medical Ctr, Osaka, Japan, ³Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ⁴Division of Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁵Rheumatology, Osaka-Minami Medical Ctr, Osaka, Japan, ⁶Osaka-Minami Medical Ctr, Kawachinagano, Japan
Background/Purpose: Biologiccs (Bio) have shown outstanding efficacy and became one of the most effective drugs in the treatment of RA. However, several issues remain, including…

« Previous Page
1
…
6
7
8
9
10
…
29
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.